EUVIMEDEUVIMED entdecken
Crossref

Bemcentinib enhances sensitivity to estrogen receptor inhibitors in breast cancer cells

Gyeongmi Kim, Se Hee Ahn, Se-Kyeong Jang, Selim Kim, Hyunggee Kim, Ki Soo Park, Hyeon-Ok Jin, Chan Sub Park, Min-Ki Seong, Hyun-Ah Kim, In-Chul Park

The International Journal of Biochemistry & Cell Biology · 2025

DOI: 10.1016/j.biocel.2025.106750 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The International Journal of Biochemistry & Cell Biology, 2025. Verfasst von Gyeongmi Kim und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Fusion Radiology Research, Korea Institute of Radiological and Medical Sciences, Seoul 01812, Republic of Korea; Department of Biotechnol…. Hauptthemen laut MEDLINE: Breast Neoplasms, Receptors, Estrogen, Drug Resistance, Neoplasm, Benzocycloheptenes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Korea Ministry of Science and ICT, NRF.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Estrogen receptor (ER)-positive breast cancer accounts for a substantial proportion of breast cancer cases and is typically managed using ER inhibitors, such as tamoxifen and fulvestrant. However, the development of resistance to these therapies is a significant clinical challenge, and the improvement of therapeutic strategies is crucial. This study aimed to investigate the potential of bemcentinib, a well-known AXL inhibitor, to enhance the sensitivity of MCF7 breast cancer cells to 4-hydroxytamoxifen (4-OHT) and fulvestrant. Our findings revealed that bemcentinib effectively decreased S6K1 phosphorylation and synergistically induced cell death when used in combination with ER inhibitors. Bemcentinib treatment also unexpectedly activated STAT3, and inhibition of STAT3 enhanced cell death induced by bemcentinib and 4-OHT. Notably, the combination of bemcentinib and 4-OHT effectively induced cell death even in tamoxifen-resistant MCF7 cells (MCF7-TR), highlighting its potential to overcome tamoxifen resistance. Interestingly, AXL knockdown did not enhance the sensitivity to 4-OHT or affect S6K1 signaling in either MCF7 or MCF7-TR cells, suggesting that the sensitizing effect of bemcentinib through S6K1 inhibition may be independent of AXL expression. Our findings suggest that bemcentinib treatment, particularly in combination therapy, could be a promising strategy for improving treatment efficacy and overcoming tamoxifen resistance in ER-positive breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsReceptors, EstrogenDrug Resistance, NeoplasmBenzocycloheptenesEstrogen Receptor AntagonistsHumansMCF-7 CellsFemaleTamoxifenAxl Receptor Tyrosine KinaseDrug SynergismReceptor Protein-Tyrosine KinasesProto-Oncogene ProteinsRibosomal Protein S6 Kinases, 70-kDaFulvestrantPhosphorylationTriazoles

Stichwörter der Autor:innen

BemcentinibEstrogen receptor-positive breast cancerS6K1STAT3Tamoxifen resistance

Substanzen

bemcentinibReceptors, EstrogenafimoxifeneTamoxifenBenzocycloheptenesAxl Receptor Tyrosine KinaseEstrogen Receptor AntagonistsReceptor Protein-Tyrosine KinasesProto-Oncogene ProteinsRibosomal Protein S6 Kinases, 70-kDa

Autor:innen und Institutionen

  • Division of Fusion Radiology Research, Korea Institute of Radiological and Medical Sciences, Seoul 01812, Republic of Korea; Department of Biotechnology, College of Life Science and Biotechnology, Korea University, Seou…
  • Division of Fusion Radiology Research, Korea Institute of Radiological and Medical Sciences, Seoul 01812, Republic of Korea; Department of Biological Engineering, Konkuk University, Seoul 05029, Republic of Korea.
  • Division of Fusion Radiology Research, Korea Institute of Radiological and Medical Sciences, Seoul 01812, Republic of Korea.
  • Department of Biotechnology, College of Life Science and Biotechnology, Korea University, Seoul 02841, Republic of Korea.
  • Department of Biological Engineering, Konkuk University, Seoul 05029, Republic of Korea.
  • KIRAMS Radiation Biobank, Korea Institute of Radiological and Medical Sciences, Seoul 01812, Republic of Korea.

Förderung

  • Korea Ministry of Science and ICT
  • NRF

Zitieren

APA

Kim, G., Ahn, S. H., Jang, S. K., Kim, S., Kim, H., Park, K. S., Jin, H. O., Park, C. S., Seong, M. K., Kim, H. A., & Park, I. C. (2025). Bemcentinib enhances sensitivity to estrogen receptor inhibitors in breast cancer cells. The International Journal of Biochemistry & Cell Biology. https://doi.org/10.1016/j.biocel.2025.106750

Vancouver

Kim G, Ahn SH, Jang SK, Kim S, Kim H, Park KS, et al. Bemcentinib enhances sensitivity to estrogen receptor inhibitors in breast cancer cells. The International Journal of Biochemistry & Cell Biology. 2025. doi:10.1016/j.biocel.2025.106750

BibTeX
@article{Kim2025,
  author = {Kim, Gyeongmi and Ahn, Se Hee and Jang, Se-Kyeong and Kim, Selim and Kim, Hyunggee and Park, Ki Soo and Jin, Hyeon-Ok and Park, Chan Sub and Seong, Min-Ki and Kim, Hyun-Ah and Park, In-Chul},
  title = {Bemcentinib enhances sensitivity to estrogen receptor inhibitors in breast cancer cells},
  journal = {The International Journal of Biochemistry & Cell Biology},
  year = {2025},
  doi = {10.1016/j.biocel.2025.106750}
}
Kostenlos starten →